• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment of Secukinumab-induced Atopic Dermatitis-like Lesions Using Upadacitinib: A Case Report.

作者信息

Xiang Wanyan, Lin Xueping, Li Qiuju, Zheng Wenjun

机构信息

From the Department of Dermatology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Department of Dermatology, Dermatology Hospital of Yulin, Guangxi, China.

出版信息

Indian J Dermatol. 2025 Sep-Oct;70(5):292-294. doi: 10.4103/ijd.ijd_446_24. Epub 2025 Sep 1.

DOI:10.4103/ijd.ijd_446_24
PMID:40918703
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12413164/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bd2/12413164/badfe346be3b/IJD-70-292-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bd2/12413164/fa39df4334ec/IJD-70-292-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bd2/12413164/70cacd7c6d7a/IJD-70-292-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bd2/12413164/badfe346be3b/IJD-70-292-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bd2/12413164/fa39df4334ec/IJD-70-292-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bd2/12413164/70cacd7c6d7a/IJD-70-292-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bd2/12413164/badfe346be3b/IJD-70-292-g003.jpg

相似文献

1
Treatment of Secukinumab-induced Atopic Dermatitis-like Lesions Using Upadacitinib: A Case Report.使用乌帕替尼治疗司库奇尤单抗诱导的特应性皮炎样皮损：一例报告
Indian J Dermatol. 2025 Sep-Oct;70(5):292-294. doi: 10.4103/ijd.ijd_446_24. Epub 2025 Sep 1.
2
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
3
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.与安慰剂（“Measure Up 1”和“Measure Up 2”研究）及度普利尤单抗（“Heads Up”研究）相比，乌帕替尼可快速改善瘙痒并清除皮肤症状：三项针对中度至重度特应性皮炎患者的3期临床试验结果
Dermatol Ther (Heidelb). 2025 Jun 2. doi: 10.1007/s13555-025-01443-w.
4
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.乌帕替尼治疗中重度特应性皮炎青少年患者的疗效和安全性：Measure Up 1、Measure Up 2 和 AD Up 随机临床试验分析。
JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391.
5
Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.度普利尤单抗治疗青少年及成人中重度特应性皮炎的真实世界疗效及耐受性。
Adv Ther. 2023 May;40(5):2509-2514. doi: 10.1007/s12325-023-02490-5. Epub 2023 Mar 21.
6
Upadacitinib and Dupilumab Demonstrate Superior Efficacy in the Treatment of Adolescent Atopic Dermatitis: A Network Meta-Analysis.乌帕替尼和度普利尤单抗在青少年特应性皮炎治疗中显示出卓越疗效：一项网状Meta分析
Int Arch Allergy Immunol. 2025;186(9):896-906. doi: 10.1159/000543397. Epub 2025 Jan 17.
7
Vitiligo exacerbation during upadacitinib treatment for atopic dermatitis and improvement following a switch to abrocitinib: a case report.乌帕替尼治疗特应性皮炎期间白癜风加重，换用阿布昔替尼后改善：一例报告
J Dermatolog Treat. 2025 Dec;36(1):2528344. doi: 10.1080/09546634.2025.2528344. Epub 2025 Aug 4.
8
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study.乌帕替尼与度普利尤单抗治疗四个身体部位中重度特应性皮炎的疗效和安全性：来自Heads Up研究的分析
Dermatology. 2025;241(1):10-18. doi: 10.1159/000542275. Epub 2024 Oct 30.
9
Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2).乌帕替尼治疗中重度特应性皮炎实现最佳治疗目标和最小疾病活动度：3期研究（Measure Up 1和2）的综合分析
Dermatol Ther (Heidelb). 2025 Jul 14. doi: 10.1007/s13555-025-01485-0.
10
Evaluation of Upadacitinib Efficacy in the Treatment of Atopic Dermatitis of Sensitive Areas.乌帕替尼治疗敏感部位特应性皮炎的疗效评估。
Dermatology. 2025;241(3):223-229. doi: 10.1159/000545227. Epub 2025 Apr 23.

本文引用的文献

1
Effect of the JAK1 Inhibitor, Upadacitinib, on Skin Barrier Repair of Eczema Elicited During Anti-Interleukin-17 Treatment for Psoriasis.JAK1抑制剂乌帕替尼对银屑病抗白细胞介素-17治疗期间引发的湿疹皮肤屏障修复的影响。
Dermatitis. 2024 Sep-Oct;35(5):537-539. doi: 10.1089/derm.2023.0298. Epub 2023 Dec 29.
2
Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series.乌帕替尼治疗银屑病合并特应性皮炎：病例系列
J Dermatolog Treat. 2023 Dec;34(1):2183729. doi: 10.1080/09546634.2023.2183729.
3
The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
托法替布、培非替尼、索利替尼、巴瑞替尼、阿布昔替尼和德瓦鲁单抗治疗斑块状银屑病的疗效和安全性：一项网状荟萃分析。
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):1937-1946. doi: 10.1111/jdv.18263. Epub 2022 Jun 9.
4
Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis.无局部皮质类固醇的靶向全身疗法治疗中度至重度特应性皮炎的比较疗效：系统评价和网状Meta分析
Dermatol Ther (Heidelb). 2022 May;12(5):1181-1196. doi: 10.1007/s13555-022-00721-1. Epub 2022 Apr 18.
5
Phenotypic switch from atopic dermatitis to psoriasis during treatment with upadacitinib.在使用乌帕替尼治疗期间，特应性皮炎向银屑病的表型转换。
Clin Exp Dermatol. 2022 May;47(5):986-987. doi: 10.1111/ced.15104. Epub 2022 Feb 2.
6
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.度普利尤单抗联合局部皮质类固醇治疗青少年和成人中重度特应性皮炎（AD Up）的安全性和有效性：一项随机、双盲、安慰剂对照、3 期临床试验的结果。
Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21.
7
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.乌帕替尼治疗中重度特应性皮炎成人患者：一项随机、安慰剂对照试验的 16 周结果。
J Allergy Clin Immunol. 2020 Mar;145(3):877-884. doi: 10.1016/j.jaci.2019.11.025. Epub 2019 Nov 29.
8
Atopic-like dermatitis after secukinumab injection: A case report.司库奇尤单抗注射后出现类特应性皮炎：一例报告。
Dermatol Ther. 2019 Jan;32(1):e12751. doi: 10.1111/dth.12751. Epub 2018 Nov 11.
9
Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.司库奇尤单抗治疗中重度斑块状银屑病老年患者的疗效和安全性：III期研究的汇总分析
Drugs Aging. 2018 Feb;35(2):135-144. doi: 10.1007/s40266-018-0520-z.
10
Mutual antagonism of T cells causing psoriasis and atopic eczema.导致银屑病和特应性皮炎的T细胞相互拮抗。
N Engl J Med. 2011 Jul 21;365(3):231-8. doi: 10.1056/NEJMoa1104200.